-C Mitsiades Researcher Activity Profile

Research Author Detailed Information 

C Mitsiades Publication Rate By Year

C Mitsiades has published 1 paper(s) in 2001, 4 paper(s) in 2006, 5 paper(s) in 2007, for a total of 10 research publications in total.

C C Mitsiades Author Information

LAST NAME: mitsiades

FIRST NAME: C

INITIALS: c

AFFILIATION:

Papers

C Mitsiades's Publication Record

1. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. Year Published: 2001
Department of Adult Oncology, Dana Farber Cancer Institute,Boston Massachusetts 02115, USA.
2. Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma. Year Published: 2006
Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
3. Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Year Published: 2007
The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
4. Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells. Year Published: 2007
Department of Adult Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA.
5. Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Year Published: 2007
Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA.
6. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism. Year Published: 2007
Bing Center for Waldenstrom's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
7. The treatment of relapsed and refractory multiple myeloma. Year Published: 2007
8. Lenalidomide in multiple myeloma. Year Published: 2006
Jerome Lipper Multiple Myeloma Center, Divison of Hematologic Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA. paul_richardson@dfci.harvard.edu
9. Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma. Year Published: 2006
Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA. Paul_Richardson@dfci.harvard.edu
10. Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma. Year Published: 2006
Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA. Paul_Richardson@dfci.harvard.edu